IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) Pharmaceutical or diagnostic composition comprising one or more active substances wherein the one or more active substance is/are selected from a group consisting of:

(a) active substances with a structure according to formula I-1 to I-9



Formula I-1



Formula I-2



Formula I-3



Formula I-4



Formula I-5



Formula I-6



Formula I-7



Formula I-8



Formula I-9

wherein X in formula I-2 and I-3 is H, OH, NH_2 or a halogen atom and X_1 and X_2 in formula I-4 are any heteroatom;

(b) active substances with a structure according to formula II-1 or II-2



Formula II-1



Formula II-2

(c) active substances with a structure according to formula III-1 to III-6



Formula III-1



Formula III-2



Formula III-3



Formula III-4



Formula III-5



Formula III-6

wherein X in formula III-1 and X_1 and X_2 in formula III-5 are H, OH, NH_2 or a halogen atom;

(d) active substances with a structure according to formula IV-1 to IV-6



Formula IV-1



Formula IV-2



Formula IV-3



Formula IV-4



Formula IV-5



Formula IV-6

X_1 and X_2 in formula IV-6 are selected from H, F, I, Br or Cl, OH or OA, SH or SA, NH_2, NHA_1 or NA_1A_2 or A and wherein A and/or A_1 and A_2 is/are a branched, straight-chain or cyclic alkyl or heteroalkyl group with up to 7 carbon atoms;

(e) active substances with a structure according to formula V-1 to V-4



Formula V-1



Formula V-2



Formula V-3



Formula V-4

(f) active substances with a structure according to formula VI-1 or VI-2



Formula VI-1



Formula VI-2

wherein R_1 to R_9 and S_1 to S_3 are selected from

(i) H, OH, NH_2 or a halogen atom;

(ii) single- or multi-branched or straight-chain alkyl or heteroalkyl groups with one or two rings and up to 10 carbon atoms;

(iii) cyclic alkyl or heteroalkyl groups with 1 or 2 rings or aryl or heteroaryl groups with up to 10 carbon atoms each; and

wherein for the structure of Formula VI-1, the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 0, 1, 2, 3 or 4 substituents, each selected from a group consisting of Cl, Br and I; and

wherein for the structure of Formula VI-2, the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 0, 1, 2, 3 or 4 substituents, each selected from a group consisting of Cl, Fl, Br and I.

2. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the halogen atoms are selected from the group consisting of I, Cl, Br and F.

3. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 1, 2, 3 or 4 heteroatoms each.

4. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 3, wherein the heteroatoms are selected from a group consisting of N, O, and S.

5. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 1, 2, 3 or 4 substituents each.

6. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 5, wherein the substituents are selected from a group consisting of Cl, F, Br and I.

7. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein R_1 and R_2, R_2 and R_3, R_3 and R_4, R_4 and R_5, R_5 and R_6, R_6 and R_7, R_7 and R_8 and/or R_8 and R_9 are bridged via further atoms.

8. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula I-5 or I-7 is selected from:



Anthraquinone



1,8-Dihydroxy-anthraquinone (Danthron)



1,8-Dihydroxy-10H-anthracene-9-one

(Dithranol/ Anthralin)



1,8-Dihydroxy-3-methyl-10H-anthracene-9-one

(Chrysarobin)



1,2,5,8-Tetrahydroxy-anthraquinone



4-[2-(1-Amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracene-2-sulfonyl)-ethyl]-N-propyl-benzensulfoneamide; and



2-Amino-benzoic acid-6-(1-amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracene-2-yloxy)-hexyl-ester.

9. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula I-1 is selected from:



(1-Methyl-1*H*-perimidine-2-yl)-methanol



2-(1H-Imidazole-4-yl)-1H-perimidine



1-Ethyl-1*H*-perimidine



1*H*,3*H*-Perimidine-2-thione



2-Pyridine-3-yl-1H-perimidine



1,2-Dimethyl-1*H*-perimidine



4-(1H-Perimidine-2-yl)-benzonitrile



2-*p*-Tolyl-1*H*-perimidine



3-(1H-Perimidine-2-yl)-phenylamine; and



2-Pyridin-4-yl-2,3-dihydro-1*H*-perimidine.

10. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula I-2 is



8-Fluoro-1,2-dimethyl-4,5-dihydro-pyrrolo[3,2,1-ij]quinoline-6-one.

11. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula I-4 has the following formula:



12. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 11, wherein the active substance is selected from



Phenoxazine-3-one



1,9-Dimethyl-phenoxazine-3-one



7-Amino-1,9-dimethyl-phenoxazine-3-one



7-Hydroxy-1,9-Dimethyl-phenoxazine-3-one



7-Amino-8-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one (alpha-amino-orcein)



8-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one (alpha-hydroxy-orcein)



7-Amino-2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one (beta-amino-orcein)



7-Amino-2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one (gamma-amino-orcein)



2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one (beta-hydroxy-orcein)



2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one (gamma-hydroxy-orcein)



beta-amino-orceimine; and



gamma-amino-orceimine.

13. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula II-2 is selected from:



N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-*N*-(2-dimethylamino-ethyl)-formamide



N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-*N*-(2-dimethylamino-ethyl)-acetamide



7-Oxo-2-(2-piperidin-1-yl-ethylamino)-6,7-dihydro-thiazolo[4,5-*f*]quinoline-8-carbonitrile



N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-*N*-(3-dimethylamino-propyl)-formamide



N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-acetamide



2-(3-Dimethylamino-propylamino)-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinoline-8-carbonitrile



2-[(2-Diethylamino-ethyl)-ethyl-amino]-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinoline-8-carbonitrile



2-Amino-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile



2-[4-(3-Hydroxy-propyl)-piperazine-1-yl]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile; and



2-[Benzyl-(2-dimethylamino-ethyl)-amino]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile.

14. (Withdrawn) The diagnostic composition according to claim 1, wherein the active substance or at least one of the active substances is labeled.

15. (Cancel)

16. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the pharmaceutical or diagnostic composition furthermore comprises one or more pharmaceutically acceptable carriers, diluents or excipients.

17. (Previously Amended) A method for the treatment or diagnosis of a polyglutamine disease comprising administering a pharmaceutical or a diagnostic composition according to claim 1 to a subject.

18. (Previously Presented) The method according to claim 17, wherein the subject is a human being.

19. (Cancel)

20. (Previously Amended) The method according to claim 19, wherein polyglutamine disease comprises Huntington's chorea, spinocerebellar ataxias of types 1, 2, 3, 6, 7

and 17, dentatorubral pallidoluysian atrophy or spinobulbar muscular atrophy (Kennedy syndrome).

21. (Cancel)

22. (Withdrawn) The diagnostic composition according to claim 14, wherein the labeled active substance is radioactive-labeled.